Skip to main content
. 2012 Jan 31;259(9):1814–1823. doi: 10.1007/s00415-012-6414-9

Fig. 1.

Fig. 1

Change in annualized relapse rate (year prior to and year after starting natalizumab treatment for all patients in treatment for at least 12 months) by baseline Expanded Disability Status Scale score. Percentages indicate relative reductions in the ARR between the year before treatment and the year on treatment